Analyst Ratings February 24, 2026

BofA Raises Keysight to Buy After Orders Beat Expectations, Lifts Price Target to $340

Strong core order growth and a higher EPS framework prompt multiple upgrades and lift analyst sentiment for Keysight Technologies

By Priya Menon KEYS
BofA Raises Keysight to Buy After Orders Beat Expectations, Lifts Price Target to $340
KEYS

Bank of America upgraded Keysight Technologies to Buy from Neutral and increased its price target to $340, citing materially stronger-than-expected order growth and an elevated earnings outlook. The test and measurement company reported a 22% year-over-year increase in core orders for the fiscal first quarter and raised its fiscal 2026 adjusted EPS growth target to above 20% year-over-year, implying adjusted EPS of at least $8.59. UBS also raised its price target to $340 while keeping a Buy rating, and InvestingPro analysis suggests the shares may be overvalued at current market levels.

Key Points

  • BofA upgraded Keysight Technologies to Buy from Neutral and raised its price target to $340 from $195 based on stronger-than-expected order growth and improved guidance.
  • Keysight reported core orders up 22% year-over-year in the fiscal first quarter, exceeding BofAs 11% expectation, and raised fiscal 2026 adjusted EPS growth guidance to more than 20%, implying at least $8.59 in adjusted EPS.
  • UBS also lifted its price target to $340 and kept a Buy rating; InvestingPro analysis suggests the shares may be overvalued at current market levels given a trailing P/E of 59.84.

Bank of America Securities has moved Keysight Technologies from a Neutral to a Buy rating and lifted its price target to $340 from $195 after the test and measurement specialist reported stronger-than-expected order trends and updated earnings guidance. The stock has climbed to $300.35, delivering a 47% return over the last six months and trading close to its 52-week high.

Keysight reported that core orders expanded 22% year-over-year in the fiscal first quarter ended in January, comfortably ahead of BofAs 11% growth expectation. According to BofA analyst David Ridley-Lane, the strength in orders was broad-based across the company's portfolio.

Following the quarter, Keysight raised its fiscal 2026 framework for adjusted earnings-per-share growth to more than 20% year-over-year, an increase from a prior outlook of more than 10%. That updated framework implies adjusted EPS of $8.59 or higher for fiscal 2026, which sits above the market consensus of $8.11.

BofAs new $340 price target is calculated using 33 times the firm's raised 2027 adjusted EPS estimate, compared with the previous target that was based on 21 times earnings. The bank noted that the 33 times multiple represents a premium to the 31 times average among peers. By contrast, Keysight currently trades at a trailing price-to-earnings ratio of 59.84, and InvestingPro analysis indicates the shares may be overvalued at current market prices.

The firm highlighted that the valuation premium reflects Keysight's above-average margins and an industry-leading share in the test and measurement sector.

Financial results for the first quarter of fiscal 2026 reinforced the upbeat tone. Keysight posted earnings per share of $2.17, ahead of the $2.00 forecast, and reported revenue of $1.6 billion versus an anticipated $1.54 billion. Management's updated guidance followed the stronger-than-expected order intake and included a robust outlook for the second quarter, with anticipated adjusted EPS and revenue ahead of analyst estimates.

UBS responded to the company's results and outlook by raising its price target on Keysight from $230 to $340 while maintaining a Buy rating, citing the strong first-quarter performance and an unexpectedly solid second-quarter outlook. Bank of America's upgrade also cited the companys raised guidance and the marked order strength.

Together, the analyst actions and Keysights revised guidance reflect a shift in sentiment among sell-side analysts toward a more constructive view on the company's near-term revenue and earnings trajectory. At the same time, market-level valuation metrics indicate the shares are trading at elevated multiples relative to both the firms historical measures and some peer metrics.


Context and market impact

Keysight's stronger order book and heightened EPS framework are primary drivers behind the recent analyst repositioning. The developments matter for investors focused on instrumentation and test-equipment suppliers, as well as for broader technology hardware and capital-equipment markets where order trends and margin profiles influence valuations and supply-chain planning.

What remains limited in the public disclosures

The companys commentary centers on the order growth and upgraded EPS framework, but publicly available remarks do not provide additional detail on the drivers beneath the order strength beyond it being broad-based, nor do they quantify the companys backlog conversion timeline in dollar terms.

Risks

  • Valuation risk - The stock trades at a high trailing P/E of 59.84 and BofAs target uses a 33 times multiple, a premium to the peer average, which introduces risk if market sentiment or fundamentals shift. (Impacted sectors: Technology hardware, Capital equipment)
  • Execution uncertainty - While order growth was described as broad-based, the company has not provided detailed public disclosure on the durability or backlog conversion timeline of those orders, which could affect revenue and cash-flow timing. (Impacted sectors: Test equipment, Supply-chain dependent manufacturing)
  • Market expectation risk - Analysts have raised targets and ratings following the quarter; elevated expectations increase downside sensitivity should future quarters fail to sustain the current pace of order growth or margin expansion. (Impacted sectors: Equity markets, Technology)

More from Analyst Ratings

Wedbush Keeps Outperform on IBM After Steep Drop Tied to Anthropic Announcement Feb 24, 2026 Leerink Keeps Outperform on Fulcrum After Full PIONEER Phase 1b Data; Price Target Unchanged Feb 24, 2026 Baird Lowers Highwoods Properties Price Target, Flags Longer Growth Timeline Feb 24, 2026 Rosenblatt Reaffirms Buy on AMD After Expanded Meta Agreement Feb 24, 2026 BofA Holds Underperform on Fulcrum Therapeutics, $7 Target Stays Despite Clinical Progress Feb 24, 2026